导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.35% | 1561/4773 |
| 近一周 | -1.47% | 1147/5458 |
| 近一月 | -2.63% | 1636/5421 |
| 近一季 | -4.63% | 2422/5205 |
| 近半年 | 1.42% | 1107/4920 |
| 近一年 | 7.72% | 1420/4361 |
| 近两年 | 50.70% | 1466/2954 |
| 近三年 | 31.27% | 1018/2253 |
| 成立以来 | 96.16% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.78% 2905/4961 |
17.32% 1474/5312 |
- - |
- - |
| 2025 | 20.87% 2076/4813 |
2.35% 1402/3635 |
2.22% 1749/4076 |
13.56% 2980/4524 |
1.74% 1233/4813 |
| 2024 | 14.39% 1050/3463 |
4.17% 478/2808 |
-1.28% 1022/3014 |
13.65% 2141/3129 |
-2.12% 1968/3463 |
| 2023 | -9.52% 1180/2656 |
3.71% 1143/2280 |
-3.22% 755/2385 |
-2.83% 761/2515 |
-7.22% 2089/2655 |
| 2022 | -19.84% 906/2207 |
-12.51% 623/1919 |
5.97% 803/2016 |
-14.20% 1045/2113 |
0.78% 1452/2208 |
| 2021 | -0.33% 748/1822 |
-0.71% 387/1255 |
7.13% 698/1330 |
-6.53% 951/1466 |
0.25% 1152/1822 |
| 2020 | 39.42% 333/1250 |
-7.56% 553/1028 |
15.76% 477/1067 |
14.40% 279/1164 |
13.90% 325/1184 |
| 2019 | 44.57% 168/1092 |
28.38% 313/754 |
1.58% 120/804 |
3.90% 228/850 |
6.69% 571/918 |
| 2018 | -22.68% 256/834 |
- - |
- - |
- - |
-13.26% 521/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 宏利沪深300指数C VS. 长安沪深300非周期A(740101) |